MDSure

The MDSURE method for diagnosis and treatment of people diagnosed with cancer, applies latest cancer research with personalized adjuvant nutritional plan that might operate deprivation and apoptosis mechanisms in cancer patients.

The method is based on a novel plasma metabolic test developed in Japan that enables profiling of the metabolic type of the person and isolate the nutritional needs of the patient, necessary to deplete its growth and operate death mechanisms. The method is mainly nutritional, and based on solid scientific material. The plan, including the tests, the nutrition, the adjuvant chemotherapy, the food and drug supplements and other surrounding methods that are offered, gives the patient the tools to cope with the disease, and therefore it almost immediately creates a better feeling for the patient, and better endurance through the treatments offered. It is important to emphasize that we do not offer a magic bullet that would cure the disease. An accurate adherance to the program is a most important factor for success.  Our message is to carefully and scientifically analyze each patient, using the knowledge available to us from most advanced research studies, and close the gap between those and the actual options that the cancer patient face. We treat food, food supplements and the chemical reactions that occur through the body mind interactions as powerful medicines. We offer our help to cooperate with the patient’s caring physician, and the family, and in accord with all other palliative treatments that the patient receives.

The method is being developed by Dr. Dorit Arad, a interdisciplinary chemist with rich academic background from Technion, Tel Aviv University and UCSF, and biotechnology experience in rational drug design from US pharmaceutical companies, (eXegenics and Cornerstone). The method is protected by a PCT patent application:  WIPO Patent Application WO/2012/116229)

The method applies to:

People who were just diagnosed with the disease

People in recession for regaining strength

People whose disease came back, for regaining sensitivity of the tumor to chemotherapy

Healthy people, in risk, for prevention and balance

 

 

 

 

       Rational for Personal Adjuvant Nutrition Plan The RAMACH Method

 

It is well established that tumors exhibit a different amino acid profile and different metabolic pattern then healthy cells. Recently this feature has been established in a study that included 4000 people. The amino acid profile in blood was taken for 4000 people, establishing a specific profile for each tumor disease that is distinct to every type of cancer, even in early stages of the disease.

See: Amino Acid Profiles of Cancer Types

 

An example for a typical profile in early and late stage of breast cancer relative to healthy individuals is as follows:

 

 

 

 

It is also well known and used in diagnostics, that some cancer cells are addicted to glucose, and dependant on glucose for their energy production. This fact is widely used in diagnostics using Pet-Scan.

The fact is that different cancer cells get it's energy, not only from glucose, but from different sources.

We identify those sources, and provide a personalized solution for each patient. 

 

We perform a metabolic test that profiles all amino acids, and metabolic pattern of the tumor. The test is performed from blood samples taken in Israel and sent to the US. The results of the test are analyzed and used to construct a personalized diet complemented by an amino acid formula that lacks specific amino acids that the tumor consumes. Often these amino acids are Methionine and phenylalanine. The formula is enriched with the derivatives and metabolites of the lacking amino

acids, and enriched with amino acids and supplements that are found spare in the test.

 

Thus, we take the diagnostic features of cancer cells one step further towards treatment. (Dorit Arad, PCT patent application,(WIPO Patent Application WO/2012/116229 ) see MDSure's patent publication.   

 

It has been shown in several cases that depriving specific amino acid nutrients from cancer cells cause shrinkage of the tumor, and more importantly, sensitization of the tumor towards chemotherapy.

For example, there is a drug based on asparagine decomposing enzyme – asparaginase, that prevents the asparagine as a nutrient to derive cancer cells targets. (Asparagine for Leucemia treatment)

Another  study (tissue culture) determined the effect of tyrosine (Tyr) and phenylalanine (Phe) deprivation on protein expression and phosphorylation of mitogen-activated protein kinase kinase 4 (MKK4)/stress-activated protein/Erk kinase (SEK1).

Similarly, arginine restriction (pdf file) seem a promising direction to treat cancer.

 

Some clinical trials have shown that Methionine restriction has a positive effect on cell sentitization for chemotherapy

 

 

A clinical trial that applies dietary Methionine restriction pus Temozolomide for recurrent GBM has started in M.D. Anderson a few years ago, and  is active now. Link for the study.

 

During our seven years of clinical activity, we already have several successful documented case studies, that show improvement in imaging and cancer markers for cases for which chemotherapy (lines 3 and more) stopped working).